Ioannis Xynos

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Ken Kato, Byoung Chul Cho, Masanobu Takahashi et al. · The Lancet Oncology · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass� 45S5 dissolution

Ioannis Xynos, Alasdair J. Edgar, Lee Buttery et al. · Journal of Biomedical Materials Research · 2001 · 1.2K citations

Life Sciences, Cell Biology, Molecular Biology +14

Ionic Products of Bioactive Glass Dissolution Increase Proliferation of Human Osteoblasts and Induce Insulin-like Growth Factor II mRNA Expression and Protein Synthesis

Ioannis Xynos, Alasdair J. Edgar, Lee Buttery et al. · Biochemical and Biophysical Research Communications · 2000 · 971 citations

Medicine, Bioengineering, Biomedical Engineering +14

Bioglass ®45S5 Stimulates Osteoblast Turnover and Enhances Bone Formation In Vitro: Implications and Applications for Bone Tissue Engineering

Ioannis Xynos, Mika Hukkanen, J. Batten et al. · Calcified Tissue International · 2000 · 722 citations

Medicine, Bioengineering, Biomedical Engineering +16

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Yuichiro� Doki, Jaffer A. Ajani, Ken Kato et al. · UCL Discovery (University College London) · 2022 · 532 citations · Full text

Medicine, Oncology, Pharmacotherapy +17